#United States #Indianapolis #Roche Diagnostics #Cyclospora #TIB MOLBIOL

Roche Unveils New Cyclospora Testing Solutions Amid U.S. Health Crisis

Roche Enhances Its Cyclospora Testing Portfolio

As the cyclospora outbreak continues to impact numerous states in the U.S., Roche is stepping up its efforts to improve public health measures by introducing two new real-time PCR tests. These advanced testing options aim to support laboratories in diagnosing cyclospora infections, a growing public health concern that can lead to severe gastrointestinal issues, including debilitating diarrhea and fatigue.

Addressing the Need in Public Health

The current outbreak of Cyclospora cayetanensis is particularly troubling, affecting many individuals and placing additional stress on emergency healthcare services. In this context, Roche has collaborated with its subsidiary, TIB MOLBIOL, to produce flexible and cost-effective PCR testing solutions that cater to the dynamic needs of laboratories tasked with responding to this crisis. The tests will enable quicker, more efficient diagnosis and treatment of infected individuals, thus playing a significant role in curbing the spread of the parasite.

“Understanding disease outbreaks and how they spread can have a huge impact on public health,” stated Dan Malarek, President and CEO of Roche Diagnostics North America. “Our robust testing infrastructure and strong scientific partnerships allow us to provide solutions that facilitate labs in swiftly addressing evolving public health needs.”

Innovative Testing Solutions

The new tests launched by Roche include:
1. LightMix® Modular Cyclospora Assay (for research use only): Targeting the detection of cyclospora infection specifically using hydrolysis probe chemistry.
2. LightMix® OneTube Gastro Para 2 Assay (for research use only): A multiplex test that incorporates real-time PCR detection of multiple pathogens, including cyclospora along with others like Entamoeba histolytica and Giardia.

Both tests are designed for use with Roche’s LightCycler® 480 and LightCycler® PRO instruments, offering laboratories the flexibility of using single or multi-pathogen tests depending on their requirements. This allows labs to not only detect cyclospora but also other gastrointestinal pathogens in one go, which enhances efficiency in diagnostic settings.

Supporting Global Health Security

Roche has positioned itself as a front-runner in the field of infectious disease testing. Beyond cyclospora, the company offers a comprehensive suite of tests that help in the identification and management of various significant infectious diseases. From HIV to influenza, its testing capabilities have expanded significantly over the years, underscoring its commitment to public health.

In light of the recent cyclospora outbreak, Roche's quick development of a molecular PCR test to detect the rare Ebola Bundibugyo virus in just six days exemplifies its agility in responding to emergent health threats. The company's drive to equip healthcare systems with essential tools is pivotal in today’s increasingly challenged health environments.

The Importance of Collaboration

Roche’s acquisition of TIB MOLBIOL, finalized in December 2021, further enhances its capacity for rapid assay development targeting new infectious diseases. After more than two decades of collaboration, this strategic move aims to solidify Roche’s leadership in the PCR-testing market, ensuring that healthcare providers can swiftly address emerging health threats.

The tests mentioned are designated for research use only and not intended for diagnostic procedures. The focus on research and development highlights Roche’s long-term vision to tackle infectious diseases and improve global health outcomes.

As Roche continues to innovate in the fight against cyclospora and other infectious diseases, it stands as a beacon of hope and progress in public health endeavors. The company remains dedicated to confronting healthcare challenges that impact patients, families, and communities worldwide. For more information about their products and initiatives, you can visit Roche’s official website.